353 related articles for article (PubMed ID: 31632019)
1. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.
Mondal L; Mukherjee B; Das K; Bhattacharya S; Dutta D; Chakraborty S; Pal MM; Gaonkar RH; Debnath MC
Int J Nanomedicine; 2019; 14():8073-8094. PubMed ID: 31632019
[TBL] [Abstract][Full Text] [Related]
2. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
3. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
4. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
Tambe P; Kumar P; Paknikar KM; Gajbhiye V
Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
[TBL] [Abstract][Full Text] [Related]
5. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
Eivazi N; Rahmani R; Paknejad M
Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
7. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
Naruphontjirakul P; Viravaidya-Pasuwat K
Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
[No Abstract] [Full Text] [Related]
8. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
9. Na
Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M
Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814
[TBL] [Abstract][Full Text] [Related]
10. Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cells.
Lee YH; Chang DS
Sci Rep; 2017 Apr; 7():46688. PubMed ID: 28429764
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
12. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
13. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
Zheng G; Zheng M; Yang B; Fu H; Li Y
Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925
[TBL] [Abstract][Full Text] [Related]
14. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
15. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
[TBL] [Abstract][Full Text] [Related]
16.
Rainone P; De Palma A; Sudati F; Roffia V; Rigamonti V; Salvioni L; Colombo M; Ripamonti M; Spinelli AE; Mazza D; Mauri P; Moresco RM; Prosperi D; Belloli S
Int J Nanomedicine; 2021; 16():1943-1960. PubMed ID: 33727808
[TBL] [Abstract][Full Text] [Related]
17. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
18. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
Park J; Fong PM; Lu J; Russell KS; Booth CJ; Saltzman WM; Fahmy TM
Nanomedicine; 2009 Dec; 5(4):410-8. PubMed ID: 19341815
[TBL] [Abstract][Full Text] [Related]
19. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
